Martin Mynarek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8761514/publications.pdf

Version: 2024-02-01

62 papers	2,020 citations	430754 18 h-index	302012 39 g-index
62 all docs	62 docs citations	62 times ranked	4109 citing authors

#	Article	IF	Citations
1	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	13.7	520
2	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
3	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	0.8	160
4	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathologica, 2014, 128, 137-149.	3.9	125
5	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	0.8	121
6	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	3.9	104
7	Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation. Clinical and Developmental Immunology, 2013, 2013, 1-14.	3.3	87
8	Patient, Virus, and Treatment-Related Risk Factors in Pediatric Adenovirus Infection after Stem Cell Transplantation: Results of a Routine Monitoring Program. Biology of Blood and Marrow Transplantation, 2014, 20, 250-256.	2.0	80
9	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	0.8	58
10	Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 43-50.	0.8	50
11	Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. European Journal of Cancer, 2015, 51, 2634-2642.	1.3	44
12	Molecular characterization of histopathological ependymoma variants. Acta Neuropathologica, 2020, 139, 305-318.	3.9	43
13	Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathologica, 2021, 141, 455-466.	3.9	37
14	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	0.7	36
15	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	0.6	33
16	Malignancies after pediatric kidney transplantation: more than PTLD?. Pediatric Nephrology, 2014, 29, 1517-1528.	0.9	28
17	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
18	Variable disease progression after successful stem cell transplantation: Prospective followâ€up investigations in eight patients with Hurler syndrome. Pediatric Transplantation, 2011, 15, 861-869.	0.5	21

#	Article	IF	Citations
19	Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastomaâ€"An Experience From the HIT-REZ 1997 & 2005 Studies. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1019-1024.	0.4	21
20	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	1.9	19
21	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	0.6	19
22	Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 52-59.	0.9	18
23	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. Strahlentherapie Und Onkologie, 2021, 197, 674-682.	1.0	16
24	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma. Cancers, 2021, 13, 6077.	1.7	16
25	Primary central nervous system sarcoma with DICER1 mutationâ€"treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer, 2022, 128, 697-707.	2.0	14
26	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€“ A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	0.6	13
27	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathologica, 2021, 141, 971-974.	3.9	12
28	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	0.6	11
29	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. American Journal of Neuroradiology, 2019, 40, 1811-1817.	1.2	9
30	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	1.7	9
31	Followâ€up evaluation of a webâ€based pediatric brain tumor board in Latin America. Pediatric Blood and Cancer, 2021, 68, e29073.	0.8	7
32	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	1.4	6
33	Refining medulloblastoma subgroups. Lancet Oncology, The, 2017, 18, 847-848.	5.1	4
34	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	0.6	4
35	Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastomaâ€"an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie Und Onkologie, 2022, 198, 282-290.	1.0	4
36	Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort. Frontiers in Oncology, 2021, 11, 756025.	1.3	3

#	Article	IF	Citations
37	Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial. European Journal of Cancer, 2022, 164, 30-38.	1.3	3
38	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	1.4	2
39	Young children with medulloblastoma: important open questions and the high-risk dilemma. Neuro-Oncology, 2020, 22, 1723-1724.	0.6	1
40	PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL. Neuro-Oncology, 2020, 22, iii425-iii426.	0.6	1
41	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	0.6	1
42	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€“ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	0.6	1
43	MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY â€“ A REPORT FROM THE HIT 2000 TRIAL. Neuro-Oncology, 2020, 22, iii389-iii390.	0.6	0
44	LINC-18. FOLLOW-UP EVALUATION OF A WEB-BASED PEDIATRIC BRAIN TUMOR BOARD IN LATIN AMERICA. Neuro-Oncology, 2020, 22, iii381-iii382.	0.6	0
45	MBCL-19. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH DESMOPLASTIC/EXTENSIVE NODULAR MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING â€“ A COMPARATIVE OUTCOMES ANALYSIS OF PROSPECTIVE MULTI-CENTER EUROPEAN AND NORTH AMERICAN TRIALS. Neuro-Oncology, 2020, 22, iii392-iii392.	0.6	0
46	MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING â€“ A COMPARATIVE OUTCOMES ANALYSIS. Neuro-Oncology, 2020, 22, iii396-iii397.	0.6	0
47	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. Neuro-Oncology, 2020, 22, iii388-iii388.	0.6	0
48	Diagnostics and Diagnosis of Late Effects in Childhood Brain Tumour Survivors. , 2021, , 239-251.		0
49	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. Neuro-Oncology, 2021, 23, vi122-vi122.	0.6	0
50	MEDB-50. Assessment of cellular radiosensitivity and DNA repair in medulloblastoma cell lines and patient-derivded xenograft slice cultures. Neuro-Oncology, 2022, 24, i117-i118.	0.6	0
51	RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort. Neuro-Oncology, 2022, 24, i11-i12.	0.6	0
52	MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort. Neuro-Oncology, 2022, 24, i118-i118.	0.6	0
53	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. Neuro-Oncology, 2022, 24, i42-i43.	0.6	0
54	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. Neuro-Oncology, 2022, 24, i113-i114.	0.6	0

#	Article	IF	Citations
55	MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	0.6	0
56	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	0.6	0
57	MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection. Neuro-Oncology, 2022, 24, i108-i108.	0.6	0
58	QOL-04. Histology, treatment, and extent of pretreatment hydrocephalus are major determents of neurocognitive outcome for survivors of pediatric posterior fossa tumors - report from the German HIT-studies. Neuro-Oncology, 2022, 24, i133-i134.	0.6	0
59	QOL-10. Treatment-induced leukoencephalopathy in pediatric medulloblastoma survivors and its impact on long-term neurocognitive functioning. Neuro-Oncology, 2022, 24, i135-i135.	0.6	0
60	EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and withoutNF2 mutation. Neuro-Oncology, 2022, 24, i44-i45.	0.6	0
61	MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?. Neuro-Oncology, 2022, 24, i108-i108.	0.6	0
62	EPEN-06. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, i39-i39.	0.6	0